Oncternal Therapeutics, Inc. (ONCT)
$0.431
Rating:
Recommendation:
-
| Symbol | ONCT |
|---|---|
| Price | $0.431 |
| Beta | 1.305 |
| Volume Avg. | 0.15M |
| Market Cap | 25.416M |
| Shares () | - |
| 52 Week Range | 0.26-1.33 |
| 1y Target Est | - |
| DCF Unlevered | ONCT DCF -> | |
|---|---|---|
| DCF Levered | ONCT LDCF -> | |
| ROE | 34.82% | Strong Buy |
| ROA | -95.36% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | -0.18% | Neutral |
| P/E | -0.60 | |
| P/B | -0.13 | Neutral |
Latest ONCT news
About
Download (Excel)Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T) product candidate that targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. Oncternal Therapeutics, Inc. has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. has a research collaboration with Celularity Inc. to evaluate placental derived-cellular therapies targeting ROR1. The company is headquartered in San Diego, California.